

Human IL-37/IL-1F7 Antibody

Antigen Affinity-purified Polyclonal Goat IgG Catalog Number: AF1975

DESCRIPTION			
Species Reactivity	Human		
Specificity	Detects human IL-37/IL-1F7 in direct ELISAs and Western blots. In direct ELISAs, less than 2% cross-reactivity with recombinant human (rh) FIL1δ, rhFIL1ε, rhFIL1 eta, rhIL-1α, rhIL-1β, rhIL-18, and rhIL-1 H1 is observed.		
Source	Polyclonal Goat IgG		
Purification	Antigen Affinity-purified		
Immunogen	en E. coli-derived recombinant human IL-37/IL-1F7 Lys27-Asp192 Accession # Q9NZH6-2		
Formulation	Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. See Certificate of Analysis for details. *Small pack size (-SP) is supplied either lyophilized or as a 0.2 μm filtered solution in PBS.		

APPLICATIONS

Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.

	Recommended Concentration	Sample
Western Blot	2 μg/mL	See Below

DATA

Detection of Human IL-37/IL-1F7 by Western Blot. Western blot shows lysates of human peripheral blood mononuclear cells (PBMCs) untreated (-) or treated (+) with 2 µg/mL LPS for 24 hours and THP-1 human acute monocytic leukemia cell line untreated (-) or treated (+) with 10 µg/mL LPS for 3 hours and 200 nM PMA for 24 hours. PVDF membrane was probed with 2 $\mu\text{g/mL}$ of Goat Anti-Human IL-37/IL-1F7 Antigen Affinitypurified Polyclonal Antibody (Catalog # AF1975) followed by HRPconjugated Anti-Goat IgG Secondary Antibody (Catalog # HAF017). A specific band was detected for IL-37/IL-1F7 at approximately 17 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 1.

PREPARATION AND STORAGE

Reconstitution Reconstitute at 0.2 mg/mL in sterile PBS

Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.

*Small pack size (-SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °C

- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 6 months, -20 to -70 °C under sterile conditions after reconstitution

Rev. 2/6/2018 Page 1 of 2





Human IL-37/IL-1F7 Antibody

Antigen Affinity-purified Polyclonal Goat IgG Catalog Number: AF1975

BACKGROUND

Human interleukin 1 family member 7 (IL-1F7), also named FIL-1Z, IL-1H4, and IL-1RP1, belongs to the IL-1 cytokine family, which currently has ten members. With the exception of IL-18 that maps to human chromosome 11, all other IL-1 family members map to the same cluster on human chromosome 2. Five alternatively spliced transcripts that arise through alternate exon usage have been described. These transcripts encode five different IL-1F7 isoforms (IL-1F7a through e also referred to as isofoms 1 through 5) that have distinct expression profiles. Polymorphism in the protein sequence of IL-1F7 isoforms also exists. Like IL-1 α , IL-1 β and IL-18, all of the IL-1F7 variants lack a typical signal peptide. The longest IL-1F7 transcript, referred to as IL-1F7b or IL-1F7 isoform 1, encodes a 218 amino acid (aa) residues proprotein containing a 45 aa propeptide, which is removed by caspase-1 to generate the 173 aa mature segment. Mature IL-1F7b and other IL-1F7 variants lack potential N-linked glycosylation sites. The secreted mature IL-1F7b was reported to exist as a nondisulfide linked homodimers in solution, IL-1F7 shares approximately 21%, 24%, and 30% aa sequence identity with mature IL-1 α , IL-1 α and IL-1 α , respectively. Mouse IL-1F7 has not been reported, but human IL-1F7 is active on mouse cells. IL-1F7b binds to IL-18 R α with low affinity but does not exert any IL-18 agonistic or antagonistic effects. IL-1F7b also binds to the IL-18BP to enhance the antagonistic effects of IL-18BP. It has been proposed that IL-1F7b form a trimeric complex with IL-18BP and IL-18 R α . This complex blocks IL-18 activity by sequestering the signal transducing subunit and preventing it from participating in IL-18 signaling (1-8).

References:

- 1. Smith, D.E. et al. (2000) J. Biol. Chem. 275:1169.
- 2. Kumar S. et al. (2000) J. Biol. Chem. 275:10308.
- 3. Busfield S.J. et al. (2000) Genomics 66:213.
- 4. Kumar S. et al. (2002) Cytokine 18:61.
- Bufler, P. et al. (2002) Proc. Natl. Acad. Sci. USA 99:13723.
- 6. Gao, W. et al. (2003) J. Immunol. 170:1077.
- 7. Pan, G. et al. (2001) Cytokine 13:1.
- 8. Sims, J.E. et al. (2001) Trends Immunol. 22:533.